Clinical Trials Directory

Trials / Completed

CompletedNCT04883216

Investigation of the Characteristics of Chronic Pain Developing After COVID-19

Investigation of the Characteristics of Chronic Pain Developing After COVID-19 in Patients With COVID-19

Status
Completed
Phase
Study type
Observational
Enrollment
776 (actual)
Sponsor
Istanbul University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Data on pain after COVID-19 were generally collected from hospitalized patients and only include information on acute pain conditions. However, the characteristics of the chronic pain experienced after COVID-19 are unknown. For this reason, the treatment and recommendations for patients who present with chronic pain after COVID-19 are not clear. Our goal is to determine the characteristics and risk factors of chronic pain developing in COVID-19 patients and to create specific treatment recommendations for these patient groups with further studies.

Detailed description

Data on pain developing after COVID-19 were generally collected from hospitalized patients and only include information on acute pain conditions seen after the ilness. It is noteworthy that headache and musculoskeletal pain were seen common in first few weeks. However, the characteristics (mechanical, inflammatory, central sensitization, anxiety-related, etc.) of the chronic pain experienced are unknown. For this reason, the treatment and recommendations for patients who present with chronic pain after COVID-19 are not clear. Our goal is to determine the characteristics and risk factors of chronic pain developing in COVID-19 patients and to create specific treatment recommendations for these patient groups with further studies.

Conditions

Timeline

Start date
2021-03-24
Primary completion
2021-12-31
Completion
2021-12-31
First posted
2021-05-12
Last updated
2022-04-19

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT04883216. Inclusion in this directory is not an endorsement.